Reduced expression of MTUS1 mRNA is correlated with poor prognosis in bladder cancer

Xiao,Jun; Chen,Jun-Xing; Zhu,Yu-Ping; Zhou,Lin-Yu; Shu,Qi-An; Chen,Ling-Wu

doi:10.3892/ol.2012.673

Reduced expression of MTUS1 mRNA is correlated with poor prognosis in bladder cancer

Authors:
- Jun Xiao
- Jun-Xing Chen
- Yu-Ping Zhu
- Lin-Yu Zhou
- Qi-An Shu
- Ling-Wu Chen
View Affiliations

Affiliations: Department of Urology, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui, P.R. China, Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China
Published online on: April 5, 2012 https://doi.org/10.3892/ol.2012.673
Pages: 113-118

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mitochondrial tumor suppressor 1 (MTUS1) is a newly identified candidate tumor suppressor gene. Previous studies have demonstrated that the expression status of MTUS1 is altered in several types of tumors. However, its clinical significance for bladder cancer patients remains undetermined. In this study, we detected the expression of MTUS1 mRNA in bladder tumors and paired normal samples obtained from 5 patients using semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR). A significant downregulation of MTUS1 mRNA expression was observed in the tumor tissues compared with the corresponding normal bladder tissue (P<0.001). We further tested the expression of MTUS1 mRNA in 55 bladder cancer tissues and 10 adjacent normal bladder tissues by quantitative real-time RT-PCR. Correlations between MTUS1 and clinicopathological features and prognosis were investigated by statistical analyses. The results showed that MTUS1 expression was correlated with tumor grade, stage, size and number (P<0.001, P<0.001, P=0.034 and P=0.029, respectively). Patients with low levels of MTUS1 mRNA expression had a poor prognosis compared with those with a high expression (P<0.001). Univariate and multivariate logistic regression prognostic analyses revealed that MTUS1 mRNA was an independent prognostic factor for disease-free survival in bladder cancer (P<0.05). In conclusion, these data suggest that MTUS1 is significant in the progression of bladder cancer and that the status of MTUS1 mRNA expression is a novel prognostic marker for predicting bladder tumor disease-free survival.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Ploeg M, Aben KK and Kiemeney LA: The present and future burden of urinary bladder cancer in the world. World J Urol. 27:289–293. 2009. View Article : Google Scholar : PubMed/NCBI
3	Lei T, Mao WM, Yang HJ, et al: Study on cancer incidence through the Cancer Registry Program in 11 cities and counties, China. Zhonghua Liu Xing Bing Xue Za Zhi. 30:1165–1170. 2009.(In Chinese).
4	Jacobs BL, Lee CT and Montie JE: Bladder cancer in 2010: how far have we come? CA Cancer J Clin. 60:244–272. 2010. View Article : Google Scholar : PubMed/NCBI
5	Seibold S, Rudroff C, Weber M, Galle J, Wanner C and Marx M: Identification of a new tumor suppressor gene located at chromosome 8p21.3–22. FASEB J. 17:1180–1182. 2003.PubMed/NCBI
6	Pils D, Horak P, Gleiss A, et al: Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival. Cancer. 104:2417–2429. 2005. View Article : Google Scholar : PubMed/NCBI
7	Dexter TJ, Sims D, Mitsopoulos C, Mackay A, Grigoriadis A, Ahmad AS and Zvelebil M: Genomic distance entrained clustering and regression modelling highlights interacting genomic regions contributing to proliferation in breast cancer. BMC Syst Biol. 4:1272010. View Article : Google Scholar
8	Sayagués JM, Abad Mdel M, Melchor HB, et al: Intratumoural cytogenetic heterogeneity of sporadic colorectal carcinomas suggests several pathways to liver metastasis. J Pathol. 221:308–319. 2010.
9	Fong Y, Lin YS, Liou CP, Li CF and Tzeng CC: Chromosomal imbalances in lung adenocarcinomas with or without mutations in the epidermal growth factor receptor gene. Respirology. 15:700–705. 2010. View Article : Google Scholar : PubMed/NCBI
10	Califano D, Pignata S, Pisano C, et al: FEZ1/LZTS1 protein expression in ovarian cancer. J Cell Physiol. 222:382–386. 2010. View Article : Google Scholar : PubMed/NCBI
11	Cheng L, MacLennan GT, Zhang S, et al: Evidence for polyclonal origin of multifocal clear cell renal cell carcinoma. Clin Cancer Res. 14:8087–8093. 2008. View Article : Google Scholar : PubMed/NCBI
12	Kim JW, Cheng Y, Liu W, et al: Genetic and epigenetic inactivation of LPL gene in human prostate cancer. Int J Cancer. 124:734–738. 2009. View Article : Google Scholar : PubMed/NCBI
13	Knowles MA, Aveyard JS, Taylor CF, Harnden P and Bass S: Mutation analysis of the 8p candidate tumour suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer. Cancer Lett. 225:121–130. 2005. View Article : Google Scholar : PubMed/NCBI
14	Di Benedetto M, Bièche I, Deshayes F, et al: Structural organization and expression of human MTUS1, a candidate 8p22 tumor suppressor gene encoding a family of angiotensin II AT2 receptor-interacting proteins, ATIP. Gene. 380:127–136. 2006.PubMed/NCBI
15	Rodrigues-Ferreira S, Di Tommaso A, Dimitrov A, et al: 8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis. PLoS One. 4:e72392009. View Article : Google Scholar : PubMed/NCBI
16	Stoll M and Unger T: Angiotensin and its AT2 receptor: new insights into an old system. Regul Pept. 99:175–182. 2001. View Article : Google Scholar : PubMed/NCBI
17	Lee S, Bang S, Song K and Lee I: Differential expression in normal-adenomacarcinoma sequence suggests complex molecular carcinogenesis in colon. Oncol Rep. 16:747–754. 2006.
18	Ye H, Pungpravat N, Huang BL, et al: Genomic assessments of the frequent loss of heterozygosity region on 8p21.3–p22 in head and neck squamous cell carcinoma. Cancer Genet Cytogenet. 176:100–106. 2007.PubMed/NCBI
19	Frank B, Bermejo JL, Hemminki K, et al: Copy number variant in the candidate tumor suppressor gene MTUS1 and familial breast cancer risk. Carcinogenesis. 28:1442–1445. 2007. View Article : Google Scholar : PubMed/NCBI
20	Zuern C, Heimrich J, Kaufmann R, et al: Down-regulation of MTUS1 in human colon tumors. Oncol Rep. 23:183–189. 2010.PubMed/NCBI
21	Nouet S, Amzallag N, Li JM, et al: Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP. J Biol Chem. 279:28989–28997. 2004. View Article : Google Scholar : PubMed/NCBI
22	Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med. 10:789–799. 2004. View Article : Google Scholar : PubMed/NCBI
23	Meloche S and Pouysségur J: The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene. 26:3227–3239. 2007. View Article : Google Scholar : PubMed/NCBI